1. Han B, Li K, Wang Q, Zhang L, Shi J, Wang Z, Cheng Y, He J, Shi Y, Zhao Y, Yu H, Zhao Y, Chen W, Luo Y, Wu L, Wang X, Pirker R, Nan K, Jin F, Dong J, Li B, Sun Y. Effects of anlotinib as a third-line or further treatment on overall survival of patients with advanced non–small cell lung cancer the ALTER0303 phase 3 randomized clinical trial. JAMA Oncol. 2018 Nov 1;4(11):1569-1575. (IF 20.871)
2. Yue D, Xu S, Wang Q, Li X, Shen Y, Zhao H, Chen C, Mao W, Liu W, Liu J, Zhang L, Ma H, Li Q, Yang Y, Liu Y, Chen H, Wang C. Erlotinib versus vinorebine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial. Lancet Respir Med. 2018 Nov;6(11):863-873. (IF 21.466)
3. Wang YN, Yao S, Wang CL, Li MS, Sun LN, Yan QN, Tang SW, Zhang ZF. Clinical Significance of 4L Lymph Node Dissection in Left Lung Cancer. J Clin Oncol. 2018 Oct 10;36(29):2935-2942. (IF 26.303)